Roche’s Breast-Cancer Drug Combo Fails Primary Endpoint in Phase 3 Trial

Roche AG's investigational combination therapy for advanced breast cancer failed to meet its primary endpoint in a pivotal Phase 3 trial, according to data disclosed on March 9, 2026. The regimen, which combines an antibody-drug conjugate with a targeted kinase inhibitor, did not significantly improve progression-free survival compared to the standard of care in patients with HER2-positive, hormone-receptor-positive metastatic disease. The trial enrolled 842 participants across multiple regions, with median progression-free survival recorded at 14.2 months in the experimental arm versus 15.1 months in the control group—falling short of statistical significance. The outcome marks a major clinical setback for Roche, which had positioned the combination as a potential breakthrough for a high-unmet-need patient population. The failure now casts doubt on the drug’s regulatory path and commercial viability, potentially derailing a key growth driver for the company’s oncology portfolio. Roche, trading under the ticker ROG.DE in Frankfurt, saw its shares drop 9.3% in early European trading following the announcement, marking the steepest single-day decline in over a year. The negative reaction extended beyond Roche, dragging down broader biotech and healthcare indices. The SPDR S&P Biotech ETF (IBB) fell 3.1%, while the Health Care Select Sector SPDR Fund (XLV) dropped 1.6%. The sell-off reflects heightened caution among investors regarding late-stage oncology pipelines, especially for drugs in competitive therapeutic areas like HER2-positive breast cancer. Analysts note that the failure could lead to revaluation of other biotech firms with similar candidates in development. With the trial results now public, Roche has initiated a review of the data to determine whether any subgroup benefits or secondary endpoints offer a path forward. However, given the lack of a statistically significant improvement in the primary endpoint, regulatory approval appears unlikely without additional trials. The outcome underscores the high failure rate of late-stage oncology candidates and reinforces the volatility inherent in biotech investing.